Replies to post #25490 on Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

GetLS

You claim LC Sentinel was a Radient test..Then why was PDX going to sell LC Sentinel if it was a Radient DR-70.. That is why the combination of Dr-70 and LC Sentinel is more feasible then your theory. Provista is connected to Radient. They are researching DR-70 at no costs to them for the past 3 years. This is why PDX and William/GCDX makes more sense than your theory. William is still connected to PDX....Provista is still connected to Radient per DR-70..Therefore, William is connected to Radient..Capiche? imo Wolf

Why the accommodation? It appears 6000 dollars was collected..

NOTE 3 — NOTE RECEIVABLE



On August 27, 2010, the Company advanced $95,000 to Provista Diagnostic, Inc. (“Provista”), as a note receivable. In addition, the note included $5,000 in origination fees. In connection with the note receivable agreement, Provista agreed to deliver two separate research reports to the Company by September 30, 2010 as full satisfaction of the balance owed. If the reports were not delivered to the Company by September 30, 2010, the agreement called for a 25% increase in the principal balance. Due to Provista’s failure to deliver such reports by September 30, 2010, the Company recorded interest income of $26,327, which represents the 25% increase from the principal balance of the note plus accrued interest of $1,062. If the research reports were not delivered to the Company by September 30, 2010, then the note required five equal payments of $20,000 (totaling $100,000) on the 1st day of each month commencing on the initial interest payment date (as defined in the note) and continuing thereafter until maturity (August 27, 2011). Interest accrued on the unpaid principal balance at a rate of 12% per annum until September 30, 2010. After this date, if the reports were not delivered interest began to accrue at the rate of 18% per annum.



On October 8, 2010, the required research reports were provided to the Company as satisfaction on the principal of the note. The accrued penalty and interest of $33,046 remains unpaid as of December 31, 2010. In the light of the overall economic crisis, our intended long-term relationship going forward with Provista, and the fact that as of the date of this report the balance was not collected, the Company considered the balance uncollectible and reversed the remaining balance against interest income as of December 31, 2010.